Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
2(29%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_3
2
29%
Ph phase_1
3
43%
Ph phase_2
1
14%

Phase Distribution

3

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(4)
Other(1)

Detailed Status

Completed4
Recruiting1
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 21 (16.7%)
Phase 32 (33.3%)

Trials by Status

completed457%
recruiting114%
active_not_recruiting114%
unknown114%

Recent Activity

2 active trials
Showing 5 of 7
active_not_recruitingphase_3

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

NCT06076642
completedphase_2

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

NCT05755035
recruitingphase_3

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06747351
completedphase_1

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

NCT06935266
completedphase_1

A Study of TAK-881 and HyQvia in Healthy Adults

NCT06895967
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06076642Phase 3

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Active Not Recruiting
NCT05755035Phase 2

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Completed
NCT06747351Phase 3

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Recruiting
NCT06935266Phase 1

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

Completed
NCT06895967Phase 1

A Study of TAK-881 and HyQvia in Healthy Adults

Completed
NCT06955793

Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA

Unknown
NCT05059977Phase 1

A Study of TAK-881 in Healthy Adults

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7